FLOURISH: Following Longitudinal Outcomes to Understand, Report, Intervene and Sustain Health for Infants, Children, Adolescents who are HIV Exposed Uninfected
Principal Investigator Initiated

Principal Investigators - Dr. Kathleen M. Powis, MD, MPH, MBA | Dr. Jennifer Jao, MD, MPH | Dr. Joseph Makhema, MB.ChB, FRCP

Study Objectives 

Primary Study Aims

HIV and Malignancy in Botswana: An observational Study of Medicine Toxicity of Concurrent Treatment and Clinical Outcomes (Thabatse Study)
Principal Investigator Initiated

Principal Investigator - Dr. Scott Dryden-Peterson MD, MSc

Thabatse is a prospective cohort study which aims to evaluate the risk factors for cancer and describe the response to treatment for patients who are HIV positive and not on Antiretroviral Therapy (ART) and those on ART.

Study Objectives

The primary aims are to evaluate the important risk factors for cancer in Botswana (including HIV) and describe the response to treatment for patients without HIV, with HIV but not yet on HAART, and those with HIV and on HAART.

Human Papillomavirus (HPV) Cervical Cancer Screening Study
Principal Investigator Initiated

Principal Investigator - Dr. Rebecca Luckett, MD, MPH

Name of the Study: Evaluation of cervical cancer screening algorithms using primary high risk human papillomavirus (HPV) in Gaborone and South East District, Botswana

Completed: Recruitment of 300 women living with HIV in Gaborone, and one year follow-up of this cohort. 

On-going: Recruitment of a new cohort of 3000 women in South East District is currently underway. 50% of the cohort will be women living with HIV. 

IMPRINT NIHR Global Health Research Group
Principal Investigator Initiated

Study Objectives: The group aims to improve the diagnosis and treatment of the four major HIV-associated fungal infections of public health importance and to ensure that these improvements are made widely available to populations most commonly affected in Africa (Democratic Republic of Congo, Mozambique, Guinea, Malawi, Botswana, South Africa), and South East Asia (Vietnam). The group brings together leading academic rese

Improving TB Screening in Pregnant and Postpartum Women Living with HIV in Botswana
Principal Investigator Initiated

Principal Investigator - Melanie Dubois, MD

Study Objectives:

In Country Evaluation for the ANC panel
Principal Investigator Initiated

Study Objectives:

The primary aim of this study is to evaluate the sensitivity and specificity of the Abbot ANC panel and its usability by trained Healthcare Professionals in a non-laboratory setting.

Increasing Access to Multiple Micronutrient Supplementation – A Pilot Intervention at up to 15 Clinics in Botswana
Principal Investigator Initiated

Principal Investigator: Dr. Ellen Caniglia, ScD

Study Objectives

Innovative HIV Testing Strategy for Middle-to-Upper Income Men in a Resource-Limited Setting
Principal Investigator Initiated

Principal Investigator - Professor Mosepele Mosepele MD, MSc, | Laura Bogart PhD

Study Objectives:

Integrating Hypertension and Cardiovascular Diseases Care into Existing HIV Services Package in Botswana (InterCARE Study)
Principal Investigator Initiated

Principal Investigators - Professor Mosepele Mosepele MD, MSc | Tendani Gaolathe BS, MD | Kathleen Wirth Hurwitz

International Sexual Health and Reproductive (ISHARE) Health Survey During COVID-19
Principal Investigator Initiated

Principal Investigator - Dr. Chelsea Morroni, MD, MPH, PhD

Iron and Folic acid supplimentation and adverse birth outcomes in Botswana
Principal Investigator Initiated

Principal Investigator: Ellen Caniglia, ScD

Study iron, folic acid and multiple micronutrient supplementation and adverse birth outcomes in Botswana began in 2020.

Karabo Study: Immune Correlates of Tuberculosis and non-Tuberculosis Infectious Morbidity in Southern African HIV- Exposed, Uninfected Infants
Principal Investigator Initiated

Principal Investigator - Dr. Kathleen Powis, MD, MPH

Study Objectives

Specific Aim 1: Define TB-related and TB-independent risk factors if morbidity and mortality in the first year of life among BCG vaccinated HE and HUU infants enrolled in the Karabo Study and a second ongoing study in Cape Town, South Africa, the InFANT Study (Innate Factors Associated with Nursing Transmission; funded by Canadian Institutes of Health Reseach), using multivariable logistic regression analysis.

Linking HIV Prevention and Postpartum Care: Safety, Efficacy and Feasibility of Cabotegravir-LA PrEP in a High-Risk Breastfeeding Population in Botswana (Tshireletso Study)
Principal Investigator Initiated

Primary Objectives

Mitigating the impact of COVID-19 effects in adolescent reproductive health through self-testing: a mixed methods pilot study: “ICHEKE”
Principal Investigator Initiated

Principal Investigator - Lucy Mupfumi, PhD

Study Objectives

Mopati: A Pilot HIV Treatment Partner Intervention in Botswana
Principal Investigator Initiated

Principal Investigators - Professor Mosepele Mosepele, MD, MSc | Laura Bogart, PhD

Motsepe Wastewater Project
Principal Investigator Initiated

Principal Investigators: Prof. Sikhulile Moyo and Dr Shahin Lockman

Study Objectives: To evaluate the feasibility of testing wastewater from both urban and village settings in Botswana for;

Multi-Country Aetiology of Genital Ulcer Study (MAGUS)
Principal Investigator Initiated

Principal Investigator: Chelsea Morroni, MPH, MPhil, PhD, MBChB, DTM&H, DFSRH

Study Objectives:

Neurodevelopment In HEU Children Exposed In Utero To Dolutegravir or Efavirenz and HIV-Unexposed Children (Motheo Study)
Principal Investigator Initiated

Principal Investigator - Dr. Shahin Lockman MD, MPH | Dr. Adam Cassidy

Open-label access to dolutegravir for HIV-1 infected children and adolescents completing IMPAACT Studies P1093 and P2019: GSK205858
Principal Investigator Initiated

Principal Investigator - Dr. Shahin Lockman MD, MPH

Primary Objectives: To provide access to age appropriate formulations of dolutegravir (DTG), either as Tivicay or as fixed dose combination (FDC) abacavir/dolutegravir/lamivudine (ABC/DTG/3TC), in an open-label protocol to eligible subjects who have completed the P1093 or IMPAACT 2019 parent studies.

Phase I/II Study of the Safety, Tolerability, Acceptability, and Pharmacokinetics of Oral and Long-Acting Injectable Cabotegravir and Rilpivirine in Virologically Suppressed Children Living with HIV-1, Two to Less Than 12 Years of Age
Principal Investigator Initiated

Principal Investigator: Gaerolwe R. Masheto, MD

Study Objectives: